Noxopharm Reports Veyonda's Potential in Late-Stage Cancer at ASCO 2020

At the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, Noxopharm, a clinical-stage Australian oncology drug development company, has reported two sets of clinical data relating to the development of NOX66 (Veyonda^®) as a treatment for end-stage cancer.

The posters addressed how NOX66 may improve treatment responses in men with mCRPC and also its contribution to restoring sensitivity to apoptosis and potentially modulating the immune microenvironment of nasopharyngeal carcinoma (NPC).

"We have been unaware of any therapies under development that come close to offering an anticancer effect to anything like the same degree that we are seeing with Veyonda, and in particular, delivering this level of benefit in a well-tolerated, minimally invasive, and cost-effective manner," said Dr. Graham Kelly, Noxopharm CEO. "In the context of what has been reported at ASCO 2020, the high response rates we are seeing with Veyonda mark it as a major drug prospect."

An estimated 300,000 men die worldwide each year from prostate cancer after exhausting available treatment options. Add to that the generally high pain levels associated with the typical spread of prostate cancer to bone, and the need for a last-line treatment offering a meaningful effect once everything else has failed becomes compelling.

"This is an exciting outcome that supports our belief in the anticancer properties of Veyonda," Dr. Kelly said. "To our knowledge, this is the first time that anyone has been able to obtain a meaningful abscopal response rate in prostate cancer. Prostate cancer has developed a reputation as a cancer with poor immune responsiveness, but this data suggests that this isn't the case. Today's result positions Veyonda at the forefront of this emerging area of oncology and suggests that we have an exciting new prospective treatment for end-stage prostate cancer."

About Noxopharm

Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The company has a primary focus on the development of Veyonda^® and is the major shareholder in the non-oncology drug development company, Nyrada Inc.